NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $2.82 -0.02 (-0.70%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About CureVac Stock (NASDAQ:CVAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CureVac alerts:Sign Up Key Stats Today's Range$2.75▼$2.8450-Day Range$2.74▼$3.4452-Week Range$2.21▼$6.30Volume273,997 shsAverage Volume879,383 shsMarket Capitalization$631.34 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company OverviewCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More… A Totally New ‘Income Coin’ (Ad)Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, it's such a radical departure from what most people think of when it comes to typical income strategies, I'm calling it: The Perfect Income AltcoinClick here to get access to my 'Perfect Income Altcoin' for just $3 today. CureVac Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks79th Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 79% of companies evaluated by MarketBeat, and ranked 253rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.05 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCureVac has a PEG Ratio of 2.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.12% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in CureVac has recently decreased by 13.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.86 Percentage of Shares Shorted5.12% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in CureVac has recently decreased by 13.07%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News SentimentN/A News SentimentCureVac has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.Search Interest3 people have searched for CVAC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added CureVac to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News HeadlinesCureVac: Back To Square OneOctober 8, 2024 | seekingalpha.comPfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patentsOctober 8, 2024 | reuters.comA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, it's such a radical departure from what most people think of when it comes to typical income strategies, I'm calling it: The Perfect Income AltcoinOctober 17, 2024 | Crypto 101 Media (Ad)CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firmsOctober 1, 2024 | finance.yahoo.comCureVac's cancer vaccine shows promise in early trialSeptember 15, 2024 | uk.investing.comCureVac’s Promising Cancer Vaccine Candidate CVGBM Elicits Buy RatingSeptember 13, 2024 | markets.businessinsider.comEQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressSeptember 13, 2024 | markets.businessinsider.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.21 at the beginning of 2024. Since then, CVAC shares have decreased by 33.0% and is now trading at $2.82. View the best growth stocks for 2024 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) released its quarterly earnings results on Thursday, August, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The company earned $15.55 million during the quarter, compared to the consensus estimate of $10.07 million. CureVac had a negative trailing twelve-month return on equity of 57.18% and a negative net margin of 422.66%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? Top institutional investors of CureVac include Green Alpha Advisors LLC (0.01%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings8/15/2024Today10/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,172Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+254.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E Ratio56.40 P/E Growth2.07Net Income$-281,580,000.00 Net Margins-422.66% Pretax Margin-419.62% Return on Equity-57.18% Return on Assets-38.60% Debt Debt-to-Equity Ratio0.09 Current Ratio2.29 Quick Ratio2.28 Sales & Book Value Annual Sales$65.86 million Price / Sales9.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.13Miscellaneous Outstanding Shares223,880,000Free Float219,067,000Market Cap$631.34 million OptionableOptionable Beta2.62 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CVAC) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.